Cristina P. Rodriguez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cristina P. Rodriguez has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
Sylvia M. Lee
Department of Medicine, Division of Hematology/Oncology University of Washington Seattle Washington USA
6 shared publicationsChristina S. Baik
5 shared publications- Keith D. Eaton
Fred Hutchinson/University of Washington Cancer Consortium 5 Seattle, WA
5 shared publications - Venu G. Pillarisetty
Department of Surgery, University of Washington, Seattle, Washington
5 shared publications - Bernardo Haddock Lobo Goulart
Fred Hutchinson Cancer Research Center, Seattle, WA
4 shared publications - Jenna M. Voutsinas
Department of Biostatistics, Fred Hutchinson Cancer Center, Seattle, WA
4 shared publications
Latest Publications
- 26 March 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (6) , 4964-4965
ASO Visual Abstract: Key Updates on the Version 9 AJCC/UICC Staging System for Salivary Gland Carcinoma
- 26 March 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (6) , 4964-4965
ASO Visual Abstract: Key Updates on the Version 9 AJCC/UICC Staging System for Salivary Gland Carcinoma
- 24 April 2025
- Published by Wiley in Head & Neck
- Vol. 47 (9) , 2552-2557
Dual PD ‐1 and CTLA4 Immune Checkpoint Blockade and Hypofractionated Radiation in Patients With Advanced Salivary Gland Cancers
Background: No standard systemic therapy exists for recurrent/metastatic salivary gland cancer (R/M SGC). We explored the safety and activity of nivolumab and ipilimumab with palliative hypofractionated radiation (XRT) in this population. Methods: This Phase I/II Trial enrolled R/M SGCs with evidence of progression, ECOG 0–1, no prior anti‐PD‐1 or CTLA4 therapy, measurable disease excluding the XRT site. Nivolumab 3 mg/kg iv Q2 weeks × 12 doses followed by 480 mg iv Q4 weeks × 8 doses and ipilimumab 1 mg/kg iv Q6 weeks × 4 doses was given. Twenty four gray XRT was given over three fractions, 2 weeks after the first dose of nivolumab. The primary endpoint was safety; secondary endpoints included RECIST 1.1 response (non‐radiated lesions), progression free, and overall survival. Results: Between April 2019 and May 2022, 20 pts. were enrolled, the median age was 58 (range 27–77 years), 10 (50%) were male, and 12 (60%) had ECOG 0. Five (20%) Grade 3 AEs were observed in three pts.; no Grade 4 or 5 toxicities were observed. Among 19 response‐evaluable patients, RECIST 1.1 PRs were observed in 4 (21%), in 2 pts. with salivary duct, 1 acinic cell, and 1 adenoid cystic, SD in 6 (31.5%) and PD in 9 (47.5%). With a median follow‐up of 16 months, median OS was 25 months (95% CI: [18.7, 31]) and median PFS was 7.3 months (95% CI [2.5, 18.7]). Conclusion: Nivolumab/ipilimumab and palliative XRT result in low rates of severe toxicities and modest response rates for SGC; further work is necessary to explore predictors for response.
- 24 April 2025
- Published by Wiley in Head & Neck
- Vol. 47 (9) , 2552-2557
Dual PD ‐1 and CTLA4 Immune Checkpoint Blockade and Hypofractionated Radiation in Patients With Advanced Salivary Gland Cancers
Background: No standard systemic therapy exists for recurrent/metastatic salivary gland cancer (R/M SGC). We explored the safety and activity of nivolumab and ipilimumab with palliative hypofractionated radiation (XRT) in this population. Methods: This Phase I/II Trial enrolled R/M SGCs with evidence of progression, ECOG 0–1, no prior anti‐PD‐1 or CTLA4 therapy, measurable disease excluding the XRT site. Nivolumab 3 mg/kg iv Q2 weeks × 12 doses followed by 480 mg iv Q4 weeks × 8 doses and ipilimumab 1 mg/kg iv Q6 weeks × 4 doses was given. Twenty four gray XRT was given over three fractions, 2 weeks after the first dose of nivolumab. The primary endpoint was safety; secondary endpoints included RECIST 1.1 response (non‐radiated lesions), progression free, and overall survival. Results: Between April 2019 and May 2022, 20 pts. were enrolled, the median age was 58 (range 27–77 years), 10 (50%) were male, and 12 (60%) had ECOG 0. Five (20%) Grade 3 AEs were observed in three pts.; no Grade 4 or 5 toxicities were observed. Among 19 response‐evaluable patients, RECIST 1.1 PRs were observed in 4 (21%), in 2 pts. with salivary duct, 1 acinic cell, and 1 adenoid cystic, SD in 6 (31.5%) and PD in 9 (47.5%). With a median follow‐up of 16 months, median OS was 25 months (95% CI: [18.7, 31]) and median PFS was 7.3 months (95% CI [2.5, 18.7]). Conclusion: Nivolumab/ipilimumab and palliative XRT result in low rates of severe toxicities and modest response rates for SGC; further work is necessary to explore predictors for response.
- Open Access
- 1 May 2024
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 22 (Supplement)
Updates to Treatment of Recurrent Metastatic Head and Neck Cancers
The introduction of immune checkpoint inhibitors (ICIs), such as pembrolizumab and nivolumab, has significantly improved overall survival in both the first- and second-line settings for patients with head and neck squamous cell carcinomas. In nasopharyngeal carcinomas, the combination of gemcitabine + cisplatin with PD-1 inhibitors has demonstrated impressive response rates and overall survival benefits. However, the unique immune-related adverse events associated with ICIs require patient counseling. Ongoing clinical trials are exploring novel combinations of ICIs with EGFR monoclonal antibodies, tyrosine kinase inhibitors, and therapeutic vaccines to further improve treatment outcomes. Biomarkers, such as circulating HPV-DNA and actionable molecular alterations (eg, HRAS mutations), may help guide treatment decisions and predict patient responses in the future.
- 1 May 2024
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 22 (Supplement)
Open AccessUpdates to Treatment of Recurrent Metastatic Head and Neck Cancers
The introduction of immune checkpoint inhibitors (ICIs), such as pembrolizumab and nivolumab, has significantly improved overall survival in both the first- and second-line settings for patients with head and neck squamous cell carcinomas. In nasopharyngeal carcinomas, the combination of gemcitabine + cisplatin with PD-1 inhibitors has demonstrated impressive response rates and overall survival benefits. However, the unique immune-related adverse events associated with ICIs require patient counseling. Ongoing clinical trials are exploring novel combinations of ICIs with EGFR monoclonal antibodies, tyrosine kinase inhibitors, and therapeutic vaccines to further improve treatment outcomes. Biomarkers, such as circulating HPV-DNA and actionable molecular alterations (eg, HRAS mutations), may help guide treatment decisions and predict patient responses in the future.
- 14 July 2023
- Published by Wiley in Head & Neck
- Vol. 45 (9) , 2323-2334
Radiation therapy for low‐ and high‐risk perineural invasion in head and neck cutaneous squamous cell carcinoma: Clinical outcomes and patterns of failure
Background: Perineural invasion (PNI) in head and neck squamous cell carcinoma (HNSCC) portends poor prognosis. Extent of treatment of nerve pathways with varying degrees of PNI and patterns of failure following elective neural radiotherapy (RT) remain unclear.Methods: Retrospective review of HNSCC patients with high‐risk (clinical/gross, large‐nerve, extensive) or low‐risk (microscopic/focal) PNI who underwent curative‐intent treatment from 2010 to 2021.Results: Forty‐four patients (mean follow‐up 22 months; 59% high‐risk, 41% low‐risk PNI) were included. Recurrence following definitive treatment occurred in 31% high‐risk and 17% low‐risk PNI patients. Among high‐risk patients, 69% underwent surgery with post‐operative RT and 46% underwent elective neural RT. Local control (83% low‐risk vs. 75% high‐risk), disease‐free, and overall survival did not differ between groups.Conclusions: High local control rates were achieved in high‐risk PNI patients treated with adjuvant or primary RT, including treatment of both involved and uninvolved, communicating cranial nerves, with few failures in electively treated regions.
- 14 July 2023
- Published by Wiley in Head & Neck
- Vol. 45 (9) , 2323-2334
Radiation therapy for low‐ and high‐risk perineural invasion in head and neck cutaneous squamous cell carcinoma: Clinical outcomes and patterns of failure
Background: Perineural invasion (PNI) in head and neck squamous cell carcinoma (HNSCC) portends poor prognosis. Extent of treatment of nerve pathways with varying degrees of PNI and patterns of failure following elective neural radiotherapy (RT) remain unclear.Methods: Retrospective review of HNSCC patients with high‐risk (clinical/gross, large‐nerve, extensive) or low‐risk (microscopic/focal) PNI who underwent curative‐intent treatment from 2010 to 2021.Results: Forty‐four patients (mean follow‐up 22 months; 59% high‐risk, 41% low‐risk PNI) were included. Recurrence following definitive treatment occurred in 31% high‐risk and 17% low‐risk PNI patients. Among high‐risk patients, 69% underwent surgery with post‐operative RT and 46% underwent elective neural RT. Local control (83% low‐risk vs. 75% high‐risk), disease‐free, and overall survival did not differ between groups.Conclusions: High local control rates were achieved in high‐risk PNI patients treated with adjuvant or primary RT, including treatment of both involved and uninvolved, communicating cranial nerves, with few failures in electively treated regions.
- 10 September 2022
- Published by Springer Nature
- p. 61-72
Systemic Therapy Advances in Head and Neck Cancer
- 10 September 2022
- Published by Springer Nature
- p. 61-72
Systemic Therapy Advances in Head and Neck Cancer
- 2 September 2022
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 114 (12) , 1619-1627
Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
TP53 mutation is the most frequent genetic event in head and neck squamous cell carcinoma (HNSCC), found in more than 80% of patients with human papillomavirus–negative disease. As mutations in the TP53 gene are associated with worse outcomes in HNSCC, novel therapeutic approaches are needed for patients with TP53-mutated tumors. The National Cancer Institute sponsored a Clinical Trials Planning Meeting to address the issues of identifying and developing clinical trials for patients with TP53 mutations. Subcommittees, or breakout groups, were tasked with developing clinical studies in both the locally advanced and recurrent and/or metastatic (R/M) disease settings as well as considering signal-seeking trial designs. A fourth breakout group was focused on identifying and standardizing biomarker integration into trial design; this information was provided to the other breakout groups prior to the meeting to aid in study development. A total of 4 concepts were prioritized to move forward for further development and implementation. This article summarizes the proceedings of the Clinical Trials Planning Meeting with the goal of developing clinical trials for patients with TP53-mutant HNSCC that can be conducted within the National Clinical Trials Network.
- 2 September 2022
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 114 (12) , 1619-1627
Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
TP53 mutation is the most frequent genetic event in head and neck squamous cell carcinoma (HNSCC), found in more than 80% of patients with human papillomavirus–negative disease. As mutations in the TP53 gene are associated with worse outcomes in HNSCC, novel therapeutic approaches are needed for patients with TP53-mutated tumors. The National Cancer Institute sponsored a Clinical Trials Planning Meeting to address the issues of identifying and developing clinical trials for patients with TP53 mutations. Subcommittees, or breakout groups, were tasked with developing clinical studies in both the locally advanced and recurrent and/or metastatic (R/M) disease settings as well as considering signal-seeking trial designs. A fourth breakout group was focused on identifying and standardizing biomarker integration into trial design; this information was provided to the other breakout groups prior to the meeting to aid in study development. A total of 4 concepts were prioritized to move forward for further development and implementation. This article summarizes the proceedings of the Clinical Trials Planning Meeting with the goal of developing clinical trials for patients with TP53-mutant HNSCC that can be conducted within the National Clinical Trials Network.